New method for identifying proteins should have “a major impact on the development of new biologics,” U of T researcher says
Biologics are a type of drug that results from the high-tech manipulation of our own proteins, as opposed to more traditional drugs built from synthetic chemicals. Because of their success so far, scientists are racing to create new biologics – and now, a U of T researcher has developed a way to make that process more powerful.
Philip M. Kim, an associate professor in U of T’s Donnelly Centre for Cellular and Biomolecular Research, combined high-tech computer simulation and high-throughput laboratory experiments to create what he hopes will be the most effective way to discover the proteins that are key to new biologics. His research was published online in the journal Science Advances on July 20, 2016.
“A large fraction of new therapeutics these days involve engineered proteins that latch onto a drug target, for instance on a cancer cell,” says Kim, also of the departments of molecular genetics and computer science. “Finding a protein that effectively binds to a target can feel like looking for a needle in a haystack.
“Our method should open up new opportunities to find those key proteins – and make a major impact on the development of new biologics.”
Under the traditional approach to developing a biologic, researchers identify a protein of interest and then test billions of variants, either randomly generated or from a natural source, hoping to find an effective binder. But these methods allow very little control over where and how the protein performs this crucial function on its target – a major factor in its effectiveness.
Kim and his team took a different approach. They used a computer to simulate the binding process, and then designed proteins that would work on the target. This type of theoretical approach has been in development for several decades, but is still not effective enough. So Kim combined the best of both methods. Instead of randomly creating massive libraries of variants, as with the traditional approach, he used computer modelling to generate a smaller, but intelligently designed repertoire of variants. Designing each variant allows for the tight control of all its properties, in contrast to conventional approaches.
“We showed that this method gives you binders that are somewhat stronger than what you get with the conventional approach,” says Kim. “The much smaller library also solves many technical problems, and we can screen for new, previously unscreenable, targets. It’s a very exciting time for cancer research, and for biologics.”
For Kim, the next step is to produce proteins that are important to certain types of cancer, but have not been screened before due to the difficulty producing them.
Learn more: A more powerful way to develop therapeutics?
The Latest on: Biologics
via Google News
The Latest on: Biologics
- Antengene Announces Collaboration with WuXi Biologics to Advance the Development of Innovative Oncology Medicineson October 10, 2020 at 5:32 am
Antengene Corporation, a leading innovative biopharmaceutical company dedicated to discovering, developing and commercializing global first-in-class and/or best-in-class therapeutics in hematology and ...
- GT Biopharma Announces Expanded TriKE(TM) Partnership With Cytovance Biologicson October 10, 2020 at 2:29 am
Sign $6,000,000.00 Agreement BEVERLY HILLS, CA / ACCESSWIRE / October 6, 2020 / GT Biopharma, Inc. (OTCQB:GTBP) (GTBP.PA) a company focused on ...
- Silver Spring’s Aziyo Biologics officially goes publicon October 9, 2020 at 11:28 am
Aziyo Biologics, the Montgomery County regenerative medicine company, has officially started publicly trading on the Nasdaq. Here's how it's doing.
- BlueWillow Biologics® Launches NanoBio® Protect Nasal Antiseptic Solutionon October 8, 2020 at 5:01 am
PRNewswire/ -- BlueWillow Biologics®, a clinical-stage biopharmaceutical company, is pleased to announce the launch of NanoBio® Protect (NanoBio®), the ...
- Regenerative medicine company Aziyo Biologics prices IPO at $17 midpointon October 8, 2020 at 5:00 am
A ziyo Biologics, which makes regenerative medical products for various tissue types, raised $50 million by offering 2.9 million shares at $17, within the range of $16 to $18. Ins ...
- The Daily Biotech Pulse: Gilead, Lilly COVID-19 Treatment Supply Agreements, CareDx's Positive Preannouncement, Aziyo Biologics Debuts On Wall Streeton October 8, 2020 at 4:52 am
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-Week Highs Oct. 7) 10X Genomics Inc ...
- Regenerative medicine company Aziyo Biologics prices $50M IPO, trades Thursdayon October 7, 2020 at 7:28 pm
Commercial-stage regenerative medicine company Aziyo Biologics (AZYO) prices a full-sized IPO with 2.94M shares priced at $17, the midpoint of the prior $16-18 range.Financials: 2019 revenue totaled ...
- Aziyo Biologics Announces Pricing of Initial Public Offeringon October 7, 2020 at 6:52 pm
Aziyo Biologics, Inc. today announced the pricing of its initial public offering of 2,941,176 shares of common stock, consisting of 2,205,882 shares of Class A common stock and 735,294 shares of Class ...
- Heat Biologics secures new patent related to gp96 platformon October 7, 2020 at 5:22 am
(NASDAQ:HTBX) has been issued a new US patent (Patent No. 10,780,161) covering compositions of matter that are part of Heat's gp96 platform in combination with inducible T cell co-stimulator ligand, ...
- Anti-Inflammatory Biologics Market 2020: Global Size, Growth Factors, Emerging Technologies, Major Segments, Forecast Research Report 2026on October 5, 2020 at 11:47 pm
Inflammatory Biologics Market Size” is expected to reach USD 149.80 billion by 2027, exhibiting a CAGR of 11.0% during the forecast period. The indication of an inflammatory surplus in patients with ...
via Bing News